





ILeopards and ghosts in the templeE
DMartin F. McKneally, MD, PhD‘‘Leopards break into the temple and drink to the
dregs what is in the sacrificial pitchers; this is re-
peated over and over again; finally it can be calen-
dared in advance, and it becomes part of the
ceremony.’’
—Franz Kafka
With this vivid image, bioethicist and University of
Toronto Law Professor Trudo Lemmens characterized the
engagement of industry in academic science.1 At a recent
workshop2 on the ethics of ghostwriting chaired by Lem-
mens, experienced ghostwriters described in detail how
this technique is used for marketing surgical devices and
pharmaceuticals. Talented writers prepare manuscripts de-
signed to help market commercial medical products. These
manuscripts are offered to prominent clinicians, who be-
come guest authors by adding their names and reputation
to the marketing plan after review and token editing. Hon-
oraria, advisory board salaries, and research support are of-
ten used to enhance interest in these transactions. Although
still prevalent, guest authorship is regarded as fraud in some
jurisdictions. To deal with this problem, the Journal’s pol-
icy on accepted manuscripts is to require the names of all
contributors, some of whom might otherwise remain in
the shadows as unacknowledged but well-paid ghosts. In re-
sponse to such policies, I anticipate that there will be more
transparent use of medical writers as acknowledged authors
and contributors.
In this issue, the Journal publishes a valuable article
about the kallikrein inhibitor ecallantide, a recombinant
peptide in the same class as aprotinin. Aprotinin had been
widely used to reduce surgical bleeding until marketing of
the drug was suspended because of reports of treatment-
related complications and deaths.3 The ecallantide study
was stopped because the drug was also associated with
unacceptable mortality. Of note, the study demonstrated
a beneficial effect on postoperative blood loss in the com-
parison group of patients treated with tranexamic acid,From the Department of Surgery and Joint Centre for Bioethics, University of
Toronto, and Toronto General Hospital, University Health Network, Toronto,
Ontario, Canada.
Disclosures: The author has nothing to disclose with regard to commercial support.
Portions of this editorial have appeared in a column by the author in the University of
Toronto Surgery Department newsletter.
Received for publication Aug 11, 2011; accepted for publication Sept 8, 2011;
available ahead of print Oct 19, 2011.
Address for reprints: Martin F. McKneally, MD, PhD, Ravine Research and Educa-
tion Centre, 77 Forest Grove Drive, Toronto, ON M2K 1Z4, Canada (E-mail:
martin.mckneally@utoronto.ca).
J Thorac Cardiovasc Surg 2011;142:1339-40
0022-5223/$36.00
Copyright  2011 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2011.09.045
The Journal of Thoracic and Cara fibrinolysis inhibitor made by Pharmacia & Upjohn Inc
(Bridgewater, NJ).
There was understandable concern about publication
because of the extent of involvement of industry in the
trial itself and in the production of the manuscript. Cubist
Pharmaceuticals (Lexington, Mass), the manufacturer of
ecallantide, funded the study, and editorial assistance
was provided by PharmaWrite, LLC (Princeton, NJ),
a commercial medical communications company. In addi-
tion, the first author is a company employee and stock-
holder in Cubist Pharmaceuticals, and 8 of the 9 authors
disclosed financial ties to the company. The data were
monitored by Global Research Services (Rockville, Md),
a commercial contract research organization, and analyzed
by InVent Clinical (Indianapolis, Ind), another indepen-
dent contract research organization. Nevertheless, 3 care-
ful reviewers, Associate Editor John Ikonimidis, and
Editor-in-Chief Lawrence Cohn were impressed by the
value of the clinical contribution.
In this commentary, I explain the reasoning behind the
decision to publish the article and discuss ghostwriting as
a form of commercial speech. I also sketch criteria for judg-
ing and managing publications from industry.
Should the Journal publish articles so extensively linked
to commercial companies? Although the intuitive initial re-
sponse might be negative, analysis at the rational and reflec-
tive levels leads us to a different conclusion. Rationally, we
should not exclude any class of authors categorically on the
basis of their affiliation, anymore than we would exclude
a manuscript from a particular hospital, university, or orga-
nization. No policy, precedent, principle, or bylaw pre-
cluded acceptance.
A reflective decision about publication should be
based on values. The salient values that guide our edito-
rial decisions are scientific merit, including freedom
from bias, interest to readers, and usefulness to the pro-
fession. The ecallantide article was judged to be scientif-
ically sound, interesting, and useful. So, what were
the ethical issues that caused concern on our editorial
board?
1. Commercialization of science. This is a valid concern,
but prevention is inappropriate and unrealistic. Collabo-
ration with industry has a long history and is now wide-
spread and highly productive. Industry supports the
majority of pharmaceutical research and most of the re-
search on medical devices. When this collaboration is
functioning optimally, the core values of science (eg, ac-
curacy, authenticity, logic, and truthfulness) are not com-








L 2. Commercial bias in scientific trials and reports. When
problems arise at the margins of data management,
such as decisions about exclusions, time boundaries on
sampling, and interpretation of adverse events, ‘‘the
profit motive [risks] compromising standards of scien-
tific truthfulness to a greater degree than in traditional
academic science.’’4 Authors and their institutions bear
the principal responsibility for the integrity of their
work, including its conduct and preparation for publica-
tion. Journals lack the resources to police the publication
component of this vast enterprise, although reviewers
and editors are advised to be alert against commercial
messaging. Our reviewers are warned explicitly against
‘‘language that sounds more like a package insert or ad-
vertising copy than a description of the methods.’’ Prob-
lematic manuscripts are referred to the Ethics Editor, as
in this instance.
Safeguards imposed externally include government-
mandated registration of all clinical trials, publication of
protocols, and, for some journals, obligatory access for re-
viewers to the full data. These measures create options to
monitor, verify, and strengthen the oversight of research.
The integrity of scientific publications is still largely depen-
dent on trust in the reliability of all who contribute to the
development of scientific progress. When egregious mis-
representation or fraud is discovered, the consequences
are public disgrace and loss of reputation, as in the notori-
ous cases of John Darsee5 and Hwang Woo-Suk.6 Fines
and other legal sanctions ensue if there is intent to defraud
and evidence of harm. Commercial firms may suffer finan-
cial consequences from reputational loss, but the financial
stakes are so high with blockbuster drugs and devices that
even million dollar settlements and fines are not always
a sufficient deterrent.
3. Commercial editorial assistance in the preparation of the
manuscript. This merits discussion, because there are
more than 182 medical publication companies writing
scientific articles for various clients. At the Toronto
workshop on the ethics of ghostwriting, experienced
ghostwriters told about the development, by the Interna-
tional Society of Medical Publications Professionals, of
guidelines and a certifying examination aimed at estab-
lishing an aura of professionalism in this expanding
field. Some critics view this as strategic marketing, but
harmonizing these activities with the values of the sci-
ence community could make a welcome contribution
to clarity in the scientific literature. Alastair Matheson,4
a scholarly freelance consultant and writer, told us that
a good medical communications team requires substan-
tial technical and academic expertise, including scien-
tists, statisticians, commercial analysts, publications
planners, trial designers, professional writers, and
journal specialists who know the stylistic and format1340 The Journal of Thoracic and Cardiovascular Surpreferences of particular journals, editors, and reviewers.
It will not surprise readers to learn that professionally
prepared articles have a rate of acceptance that is 4 times
higher than the usual submitted manuscript.
The article on ecallantide turned out to be an exemplary
model of commercially sponsored clinical science. I spoke
to one of the authors who helped design the trial and learned
that all authors had contributed significantly to the study
and the report. Contributions from the commercial medical
communications company were minor and acknowledged.
The manuscript was not written by ghost authors. The trial
was registered at clinicaltrials.gov, and the decision to ter-
minate the study early was based on the recommendation
of an independent data safety monitoring board. The find-
ings are distinctly unfavorable to the manufacturer of ecal-
lantide, and the report of a beneficial effect of tranexamic
acid favors a competitor. Often, a negative study such as
this might be buried by a commercial sponsor. The com-
mendable decision to submit the study for peer review cer-
tainly earned my respect and endorsement of publication.
In addition to its scientific value, the ecallantide report il-
lustrates the importance of attention by journals to conflict of
interest, and the value of conscientious commercial partici-
pation in scientific publication. Just as we set standards for
exhibitors at meetings and for advertisements in journals,
our profession can provide guidance on the management
of potential conflicts of interest in industrial authorship.
The question remains, will the acceptance of a commer-
cially run study like this one become a Trojan horse, estab-
lishing a level of trust in commercial publication that will
facilitate the acceptance of subsequent studies of less merit
or integrity? Time and experience will answer. Like the an-
cient city of Troy, our scientific journals cannot remain per-
manently behind a defensive wall, but should be cautious,
alert, and circumspect as we open the gates.
The author thanks Trudo Lemmens, Alastair Matheson, Eleanor
and Miles Shore, and a cottage full of McKneallys for helpful
comments that improved earlier versions of this editorial
commentary.
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